Roche and Exiqon Agree on Joint Marketing Approach for their RT PCR Assay Systems(PresseBox) (Penzberg, )
Roche Applied Science's RealTime ready assays offer maximized testing efficiency. Targets of choice are selectable out of gene lists of functionally related gene families or biological pathways. They can be ordered as single assays or configured as custom panel on a LightCycler® 480 Multiwell Plate. The function tested qPCR assays based on the proven Universal ProbeLibrary technology enable for optimum results, with detailed bioinformatics background information and novel errordetection features. The RealTime ready assays allow for discovery of the functionality of targets in complex biological pathways, to research their influence on processes leading to diseases or disorders.
Exiqon's miRCURY LNA(TM) Universal RT microRNA PCR system offers a combination of performance and easeofuse on the microRNA realtime PCR market. The use of LNA(TM) enhanced PCR primers secures exceptional sensitivity and specificity enabling accurate quantification of very low amounts of microRNA obtained from difficult samples such as FFPE, serum/plasma and laser capture microscopy. The product line which includes reagents for the LightCycler® 480 System consists of microRNA Readyto-Use PCR panels for expression profiling of human and rodent microRNAs, individual microRNA assays, reference genes and reagent kits.
Exiqon's products are based on the proprietary LNA(TM) technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics is developing a series of new molecular diagnostic products based on miRNA. Exiqon's goal is to gain a marketleading position for miRNAbased diagnostics. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information: www.exiqon.com.